Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Middle East News Watch.
Press releases published on July 29, 2025
Harfang annonce un nouveau partenariat d'exploration avec SOQUEM sur le projet Lac Menarik
GlobeNewswire
·
July 29, 2025
MONTRÉAL, 29 juill. 2025 (GLOBE NEWSWIRE) -- Harfang Exploration Inc. (TSX.V: HAR) (« Harfang » ou la « Compagnie ») annonce aujourd’hui la signature d’une entente d’option et de coentreprise définitive (l’« Entente ») avec SOQUEM Inc. (« SOQUEM »), une …
Ocular Therapeutix™ to Report Second Quarter 2025 Financial Results on August 5, 2025
GlobeNewswire
·
July 29, 2025
BEDFORD, Mass., July 29, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, …
NorthWest Closes First Tranche of Flow Through Financing and Upsizes Placement to Fund Work at Kwanika
GlobeNewswire
·
July 29, 2025
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, July 29, 2025 (GLOBE NEWSWIRE) -- NorthWest Copper Corp. (“NorthWest” or “the Company”) (TSX-V: NWST) is pleased to announce the closing of the …
Oroco Receives Approval for Whittle Share Payment
GlobeNewswire
·
July 29, 2025
VANCOUVER, Canada, July 29, 2025 (GLOBE NEWSWIRE) -- Oroco Resource Corp. (TSX-V: OCO; OTC: ORRCF) (“Oroco” or the “Company”) is pleased to announce that the terms of the Company’s engagement of Whittle Consulting Ltd. (“Whittle”) have received the …
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025
GlobeNewswire
·
July 29, 2025
― Announced results from the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); pociredir was generally well-tolerated with no treatment-related serious adverse events (SAEs) ― ― Observed robust and rapid pan- …
Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
GlobeNewswire
·
July 29, 2025
― Robust and clinically meaningful absolute mean fetal hemoglobin (HbF) induction of 8.6% from baseline at 12 weeks of treatment; 7 of 16 patients achieved absolute HbF levels greater than 20% ― ― Evidence of pan-cellular induction of HbF based on an …
Allot to Release Second Quarter 2025 Results and Host Conference Call on August 14, 2025
GlobeNewswire
·
July 29, 2025
Hod Hasharon, Israel, July 29, 2025 (GLOBE NEWSWIRE) -- Allot Ltd. (NASDAQ: ALLT, TASE: ALLT), a leading global provider of innovative security-as-a-service (SECaaS) and network intelligence solutions for communication service providers (CSPs) and …